Clinical Trials | September 17, 2025
Enveric clears FDA feedback milestone, prepares IND submission for EB-003
IND application for EB-003 expected in early 2026
IND application for EB-003 expected in early 2026
A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Philips and Masimo will also collaborate on the development and co-promotion of next-generation monitoring solutions
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Subscribe To Our Newsletter & Stay Updated
